Regulatory role and mechanism of Fuzheng Huayu Capsule on scar-associated macrophages in a mouse model of liver fibrosis in metabolic associated fatty liver disease

Chen ZOU; Rutao LIN; Xiao XU; Qian HUANG; Ping LIU; Yiyang HU; Xin XIN; Qin FENG

doi:10.12449/JCH251215

Volume 41 Issue 12

Dec. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(12): 2536-2544

PDF( 123601 KB)

Regulatory role and mechanism of Fuzheng Huayu Capsule on scar-associated macrophages in a mouse model of liver fibrosis in metabolic associated fatty liver disease

DOI: 10.12449/JCH251215

Chen ZOU¹,
Rutao LIN¹,
Xiao XU¹,
Qian HUANG¹,
Ping LIU^{1, 2, 3},
Yiyang HU^{1, 2, 3},
Xin XIN^{1, 2, 3
,
,
,},
Qin FENG^{1, 2, 3
,
,
,}

1.
Institute of Liver Diseases，Shuguang Hospital Affiliated to Shanghai University ofTraditional Chinese Medicine，Shanghai 201203，China
2.
Key Laboratory of Liver and Kidney Diseases，Ministry of Education，Shanghai 201203，China
3.
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine，Shanghai 201203，China

Research funding:

Shanghai Youth Technology Talents Sailing Program (23YF1448200)

More Information

Corresponding author: XIN Xin， xinxinliver@yeah.net （ORCID： 0000-0003-4899-9127）; FENG Qin， fengqin@shutcm.edu.cn （ORCID： 0000-0002-4641-1636）
Received Date: 2025-07-15
Accepted Date: 2025-08-15
Published Date: 2025-12-25

Abstract

Abstract

Objective To investigate the molecular mechanism of Fuzheng Huayu Capsule in improving liver fibrosis in metabolic associated fatty liver disease by regulating scar-associated macrophages （SAMs）. Methods A total of 24 C57 mice were randomly divided into control group （Con group）， Model group， and Fuzheng Huayu Capsule group （FZHY group）. Mice were given a high-fat diet and intraperitoneal injection of CCl₄ for six weeks to establish a model of liver fibrosis in metabolic associated fatty liver disease. The drug was given by gavage for 5 consecutive weeks since week 2 of modeling. FZHY group was administered Fuzheng Huayu Capsule via oral gavage， while the Con and Model groups received an equal volume of saline solution via oral gavage. The serum levels of liver enzymes were measured， as well as the levels of triglyceride （TG） and hydroxyproline （Hyp） in the liver. HE staining and picrosirius red staining were used to observe liver tissue. Three liver tissue samples were collected from the Model group and the FZHY group， and transcriptome sequencing was performed to investigate the molecular mechanism of Fuzheng Huayu Capsule in improving liver fibrosis in metabolic associated fatty liver disease. Western blot and RT-qPCR were used to measure the protein and/or mRNA expression levels of SAM markers （CD9 and triggering receptor expressed on myeloid cells 2 ［TREM2］）， profibrogenic genes （transforming growth factor-β1 ［TGFβ1］， platelet-derived growth factor subunit beta ［PDGFβ］， and TNF superfamily member 12 ［TNFSF12］）， and the upstream regulator activating transcription factor 3 （ATF3） in liver tissue. The serum containing Fuzheng Huayu Capsule was used for the intervention of pro-inflammatory bone marrow-derived macrophages （BMDMs） induced by lipopolysaccharide and TGF-β1， and immunofluorescence assay， Western blot， and RT-qPCR were used to measure the expression levels of TREM2 and ATF3. The independent-samples t test was used for comparison of continuous data between two groups， and a one-way analysis of variance was used for comparison between multiple groups， while the least significant difference t-test was used for further comparison between two groups. Results Compared with the Model group， the FZHY group had significant reductions in the levels of liver enzymes， the levels of TG and Hyp in the liver， NAS score， and Sirius Red staining-positive area （all P<0.01）. The RNA-seq analysis showed that differentially expressed genes were mainly enriched in chemokine signaling pathways， and Fuzheng Huayu Capsule significantly downregulated the expression of CCL2， CX3CL1， and CX3CR1（all P<0.01）. Fuzheng Huayu Capsule significantly reduced the protein and mRNA expression levels of CD9， TREM2， and ATF3 in liver tissue （all P<0.05）. In vitro， Fuzheng Huayu Capsule significantly reduced the mRNA expression levels of TGFβ1， PDGFβ， and TNFSF12 in liver tissue （all P<0.01）. Fuzheng Huayu Capsule also attenuated TREM2 fluorescence intensity in pro-inflammatory BMDMs and significantly reduced the mRNA and protein expression levels of ATF3 （all P<0.05）. Conclusion Fuzheng Huayu Capsule has a marked therapeutic effect on mice with liver fibrosis in metabolic associated fatty liver disease， possibly by downregulating the expression of ATF3 and inhibiting SAMs.
- Metabolic Associated Fatty Liver Disease,
- Liver Fibrosis,
- Fuzheng Huayu Capsules,
- Macrophages,
- Activating Transcription Factor 3,
- Mice， Inbred C57BL

FullText(HTML)

References(27)

References

[1]	ISRAELSEN M, FRANCQUE S, TSOCHATZIS EA, et al. Steatotic liver disease[J]. Lancet, 2024, 404( 10464): 1761- 1778. DOI: 10.1016/S0140-6736(24)01811-7.
[2]	HAGSTRÖM H, SHANG Y, HEGMAR H, et al. Natural history and progression of metabolic dysfunction-associated steatotic liver disease[J]. Lancet Gastroenterol Hepatol, 2024, 9( 10): 944- 956. DOI: 10.1016/S2468-1253(24)00193-6.
[3]	DO A, ZAHRAWI F, MEHAL WZ. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis(MASH)[J]. Nat Rev Drug Discov, 2025, 24( 3): 171- 189. DOI: 10.1038/s41573-024-01084-2.
[4]	PARK MD, SILVIN A, GINHOUX F, et al. Macrophages in health and disease[J]. Cell, 2022, 185( 23): 4259- 4279. DOI: 10.1016/j.cell.2022.10.007.
[5]	TARU V, SZABO G, MEHAL W, et al. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation[J]. J Hepatol, 2024, 81( 5): 895- 910. DOI: 10.1016/j.jhep.2024.06.016.
[6]	FABRE T, BARRON AMS, CHRISTENSEN SM, et al. Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation[J]. Sci Immunol, 2023, 8( 82): eadd8945. DOI: 10.1126/sciimmunol.add8945.
[7]	CUI XY, SUN QH, ZHENG LH, et al. Role of triggering receptor expressed on myeloid cells 2 in acute and chronic liver diseases[J]. J Clin Hepatol, 2025, 41( 2): 383- 388. DOI: 10.12449/JCH250228. 崔馨月, 孙全昊, 郑丽红, 等. 髓系细胞触发受体2(TREM2)在急慢性肝病中的作用[J]. 临床肝胆病杂志, 2025, 41( 2): 383- 388. DOI: 10.12449/JCH250228.
[8]	XIONG XL, KUANG H, ANSARI S, et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis[J]. Mol Cell, 2019, 75( 3): 644- 660.e5. DOI: 10.1016/j.molcel.2019.07.028.
[9]	RAMACHANDRAN P, DOBIE R, WILSON-KANAMORI JR, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level[J]. Nature, 2019, 575( 7783): 512- 518. DOI: 10.1038/s41586-019-1631-3.
[10]	XIN X, CAI BY, CHEN C, et al. Effect of fuzheng Huayu capsule on experimental non-alcoholic fatty liver fibrosis in mice[J]. Chin J Exp Tradit Med Formulae, 2021, 27( 6): 37- 45. DOI: 10.13422/j.cnki.syfjx.20210202. 辛鑫, 蔡蓓玉, 陈成, 等. 扶正化瘀胶囊对非酒精性脂肪性肝纤维化小鼠的影响[J]. 中国实验方剂学杂志, 2021, 27( 6): 37- 45. DOI: 10.13422/j.cnki.syfjx.20210202.
[11]	BAILEY JD, SHAW A, MCNEILL E, et al. Isolation and culture of murine bone marrow-derived macrophages for nitric oxide and redox biology[J]. Nitric Oxide, 2020, 100: 17- 29. DOI: 10.1016/j.niox.2020.04.005.
[12]	WATANABE Y, TSUCHIYA A, SEINO S, et al. Mesenchymal stem cells and induced bone marrow-derived macrophages synergistically improve liver fibrosis in mice[J]. STEM CELLS Transl Med, 2019, 8( 3): 271- 284. DOI: 10.1002/sctm.18-0105.
[13]	ISHIYAMA S, HAYATSU M, TORIUMI T, et al. Assessing the combined impact of fatty liver-induced TGF-β1 and LPS-activated macrophages in fibrosis through a novel 3D serial section methodology[J]. Sci Rep, 2024, 14: 11404. DOI: 10.1038/s41598-024-60845-6.
[14]	GUAN X, LIU W, CHEN JM, et al. Research advances in the clinical and basic research on Fuzheng Huayu prescription in treatment of chronic liver diseases[J]. J Clin Hepatol, 2021, 37( 6): 1449- 1453. DOI: 10.3969/j.issn.1001-5256.2021.06.048. 关茜, 刘伟, 陈佳美, 等. 扶正化瘀方治疗慢性肝病的临床与基础研究进展[J]. 临床肝胆病杂志, 2021, 37( 6): 1449- 1453. DOI: 10.3969/j.issn.1001-5256.2021.06.048.
[15]	RAO GC, PENG X, LI XQ, et al. Unmasking the Enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: From mechanism to the clinic[J]. Front Med, 2023, 10: 1294267. DOI: 10.3389/fmed.2023.1294267.
[16]	DENK H, ABUJA PM, ZATLOUKAL K. Animal models of NAFLD from the pathologist’s point of view[J]. Biochim Biophys Acta BBA Mol Basis Dis, 2019, 1865( 5): 929- 942. DOI: 10.1016/j.bbadis.2018.04.024.
[17]	TSUCHIDA T, LEE YA, FUJIWARA N, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer[J]. J Hepatol, 2018, 69( 2): 385- 395. DOI: 10.1016/j.jhep.2018.03.011.
[18]	TSOUKA S, KUMAR P, SEUBNOOCH P, et al. Transcriptomics-driven metabolic pathway analysis reveals similar alterations in lipid metabolism in mouse MASH model and human[J]. Commun Med, 2024, 4: 39. DOI: 10.1038/s43856-024-00465-3.
[19]	CHENG D, CHAI J, WANG HW, et al. Hepatic macrophages: Key players in the development and progression of liver fibrosis[J]. Liver Int, 2021, 41( 10): 2279- 2294. DOI: 10.1111/liv.14940.
[20]	REMMERIE A, MARTENS L, THONÉ T, et al. Osteopontin expression identifies a subset of recruited macrophages distinct from kupffer cells in the fatty liver[J]. Immunity, 2020, 53( 3): 641- 657. e 14. DOI: 10.1016/j.immuni.2020.08.004.
[21]	GUILLIAMS M, BONNARDEL J, HAEST B, et al. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches[J]. Cell, 2022, 185( 2): 379- 396. e 38. DOI: 10.1016/j.cell.2021.12.018.
[22]	LINK F, LI YJ, ZHAO JL, et al. ECM1 attenuates hepatic fibrosis by interfering with mediators of latent TGF-1 activation[J]. Gut, 2025, 74( 3): 424- 439. DOI: 10.1136/gutjnl-2024-333213.
[23]	LIU ZY, XIANG HY, XIANG DJ, et al. Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence[J]. Chin Med, 2022, 17( 1): 23. DOI: 10.1186/s13020-022-00579-7.
[24]	GADIPUDI LL, RAMAVATH NN, PROVERA A, et al. Annexin A1 treatment prevents the evolution to fibrosis of experimental nonalcoholic steatohepatitis[J]. Clin Sci, 2022, 136( 9): 643- 656. DOI: 10.1042/cs20211122.
[25]	SEIDMAN JS, TROUTMAN TD, SAKAI M, et al. Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis[J]. Immunity, 2020, 52( 6): 1057- 1074.e7. DOI: 10.1016/j.immuni.2020.04.001.
[26]	SHI ZM, ZHANG K, CHEN T, et al. Transcriptional factor ATF3 promotes liver fibrosis via activating hepatic stellate cells[J]. Cell Death Dis, 2020, 11: 1066. DOI: 10.1038/s41419-020-03271-6.
[27]	LI XM, LIN LF, LI YF, et al. ATF3-mediated transactivation of CXCL14 in HSCs during liver fibrosis[J]. Clin Transl Med, 2024, 14( 10): e70040. DOI: 10.1002/ctm2.70040.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(10) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (49) PDF downloads(16)

Regulatory role and mechanism of Fuzheng Huayu Capsule on scar-associated macrophages in a mouse model of liver fibrosis in metabolic associated fatty liver disease

DOI: 10.12449/JCH251215

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Regulatory role and mechanism of Fuzheng Huayu Capsule on scar-associated macrophages in a mouse model of liver fibrosis in metabolic associated fatty liver disease

DOI: 10.12449/JCH251215

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content